SITE006-0258

completed

Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE006 (GBR) (Dr. Rossi) · consented 2022-12-29

Adverse events

Serious AEs

Open data queries

Luna dropout signal

–

Adverse events

mild assessed 2026-08-18

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-01-11 (study day 4); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Neutropenia — outcome: UNKNOWN; onset 2023-02-12 (study day 36); relationship: not assessed

severe serious assessed 2026-08-18

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-03-01 (study day 53); relationship: N; serious criteria: hospitalization

mild assessed 2026-08-18

Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-04-24 (study day 107); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-06-08 (study day 152); relationship: N

moderate assessed 2026-08-18

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-06-29 (study day 173); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-09-29 (study day 265); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-12-20 (study day 347); relationship: not assessed

severe assessed 2026-08-18

Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2024-01-13 (study day 371); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.